Saudi Arabia

Executive summary

Saudi Arabia is the largest pharmaceutical market in the Middle East (~USD 9 billion) and is regulated by the Saudi Food and Drug Authority (SFDA), an autonomous statutory body established in 2003 reporting directly to the Council of Ministers. The Drug Sector within SFDA regulates medicines, biologics, biosimilars, vaccines, herbal products, and IVDs/medical devices (under separate Medical Devices Sector). SFDA's regulatory framework is built on the SFDA Law (Royal Decree M/6/2007) and the Drug Law. SFDA accepts ICH-CTD/eCTD, is an ICH observer, has applied for PIC/S membership, and operates one of the most reliance-receptive frameworks among emerging markets via the Verification Pathway (also called Abridged or SRA-reliance route) for products approved by Stringent Regulatory Authorities (SRAs: FDA, EMA, MHRA, Health Canada, TGA, Swissmedic, PMDA). Pricing is regulated by SFDA's Pricing Department using external reference pricing across ~30 countries with a complex algorithm based on country-of-origin price, reference-country averages, and therapeutic class comparators. Public procurement runs through NUPCO (National Unified Procurement Company) for MoH/MNGHA hospitals and the Saudi National Insurance under Vision 2030 reforms. The kingdom also implements Saudisation (Nitaqat) requirements for distributors and a mandatory Saudi Drug Code (RSD) on packaging.